Sign in
Not yet taking people in FrancePhase 2

Oxygen chamber therapy combined with light therapy for vitiligo

Tests hyperbaric oxygen plus light therapy in adults with widespread vitiligo.

Key facts

Who runs it
Centre Hospitalier Universitaire De Nice
Where
Nice, FranceSee the site
Registry title
Mitochondrial network modulation approach using hyperbaric oxygen (HBO) therapy and NNbUVB for treating vitiligo
Status
Not yet recruiting
Phase
Phase 2
People taking part
5 people, planned
Started
1 Feb 2026
Expected to end
1 Aug 2027
Type of study
Interventional
Record updated
28 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with non-segmental vitiligo. It tests hyperbaric oxygen (HBO) therapy combined with NNbUVB light therapy.

Age
18 years and older.
Sex
Men and women can join.
Disease stage
Non-segmental vitiligo diagnosed at least 3 months ago, active and stable. Skin involvement between 4%-60% of body surface area, not counting palms, soles or tops of the feet. At least 0.5% involvement on the face. VASI score of 3 or more.
Earlier treatment
People using UVB photosensitizing drugs (medicines that make skin sensitive to UVB light) cannot join.

Main reasons for not taking part

  • Weakened immune system, tuberculosis or latent tuberculosis, or active infection or other systemic or inflammatory disease
  • Past skin cancer or light-triggered skin disease
  • Segmental or mixed vitiligo, or more than 33% of white hair on the patches
  • Any reason that rules out hyperbaric oxygen therapy
  • Pregnant or breastfeeding women, people under guardianship or with a psychiatric condition

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Men and women diagnosed with non-segmental vitiligo for at least for 3 months
  • Patient willing and able to attend all study visits
  • ≥ 18 years old
  • Body surface area (BSA) involvement between 4%-60% inclusive, excluding involvements at palms of the hands, soles of the feet, or dorsal aspect of the feet,
  • BSA ≥0.5% involvement on the face
  • VASI ≥3
  • Active and stable vitiligo
  • For women of child-bearing age, an effective contraception (estroprogestative pill, contraceptive implant, IUD, condoms or tubal ligation) should be used for more than one month before the inclusion in the study. A urine pregnancy test (βHCG in urines) will be performed
  • Affiliation to a social security system
  • Signed informed consent

Who cannot take part

  • Participants in other clinical therapeutic studies involving a drug that could interfere with the present evaluation
  • Use of UVB photosensitizing drugs
  • Concomitant dermatosis which, in the opinion of the investigator, may interfere with the evaluation of vitiligo
  • Patients with contraindications to HBO therapy
  • Tuberculosis or latent tuberculosis
  • Vulnerable people: pregnant or breast-feeding women, minors, adult under guardianship, deprived of freedom or with psychiatric condition
  • Personal history of skin cancer or photo dermatosis
  • Any other pathological condition or therapeutic treatment identified during the initial consultation and considered a contraindication to hyperbaric exposure
  • Patients with active infection or other systemic/ inflammatory disease
  • Immunocompromised patients
  • Segmental or mixed vitiligo
  • Patients with more than 33% of leucotrichia on the lesions

Where in France

  • Centre Hospitalier Universitaire de NiceNice, FranceNot yet recruiting

About the trial

What the trial wants to find out

To assess the therapeutic efficacy of combining hyperbaric oxygen (HBO) therapy with phototherapy for the treatment of diffuse vitiligo, as measured by the change in Vitiligo Area Scoring Index (VASI) after 24 weeks of intervention.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
MitOxyVit: Mitochondrial network modulation approach using hyperbaric oxygen (HBO) therapy and NNbUVB for treating vitiligo
Plain-language title
Oxygen chamber therapy combined with light therapy for vitiligoGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
28 May 2026